Volume 29, Number 9—September 2023
Dispatch
Acute Chagas Disease Outbreak among Military Personnel, Colombia, 2021
Table
Characteristics |
Patient 1 |
Patient 2 |
Patient 3 |
Patient 4 |
Patient 5 |
Patient 6 |
Patient 7 |
No. days fever at hospital admission |
26 |
25 |
25 |
25 |
25 |
25 |
33 |
Symptoms |
Fever, asthenia, adynamia, diarrhea, vomiting, chest pain, orthopnea |
Fever, asthenia, adynamia, abdominal pain, pleuritic pain, dyspnea |
Fever, chills, vomiting, abdominal pain, pleuritic pain, dyspnea |
Fever, headache, chills, abdominal pain, diarrhea, vomiting, pleuritic pain, dyspnea |
Fever, abdominal pain, diarrhea, vomiting, dry cough, orthopnea |
Fever, asthenia, malaise, diarrhea, pleuritic pain, dyspnea |
Fever, asthenia, adynamia, diarrhea |
ICU admission |
Y |
Y |
Y |
Y |
Y |
Y |
N |
Pericardial effusion, mL |
+, 600 |
+, 450 |
+, 760 |
+, 600 |
+, 200 |
+, ND |
No effusion |
Troponin, pg/mL |
1,111 |
225 |
722 |
671 |
997.3 |
568 |
4.7 |
Echocardiography |
LVEF 29%, generalized apical hypokinesia, LVMI 131 g/m2 |
LVEF 54%, hypokinesia of apical predominance, LVMI 112 g/m2 |
LVEF 38%, decreased right ventricular filling pattern without contractility disorder, LVMI 120 g/m2 |
LVEF 28%, generalized hypokinesia, LVMI 150 g/m2 |
LVEF 35%, no contractility disorder, LVMI 120 g/m2 |
LVEF 62%, no contractility disorder, LVMI 104 g/m2 |
LVEF 60%, no contractility disorder, LVMI 72 g/m2 |
EKG |
Sinus rhythm, generalized low voltage, and anterolateral repolarization disorder |
Sinus rhythm, generalized low voltage, and anterolateral repolarization disorder |
Sinus tachycardia, generalized repolarization disorder, and low voltage |
Sinus tachycardia, generalized repolarization disorder, and low voltage |
Sinus tachycardia, generalized repolarization disorder, and low voltage |
Sinus tachycardia, generalized repolarization disorder, and low voltage |
Sinus rhythm |
Hemoglobin, g/dL |
12 |
10.1 |
10.6 |
13 |
9.5 |
12.2 |
15.6 |
Creatinine, mg/dL |
0.94 |
0.75 |
0.82 |
0.92 |
0.88 |
0.76 |
1.04 |
Thick blood smear† |
– |
– |
– |
– |
– |
– |
– |
SARS-CoV-2 rapid antigen test‡ |
– |
– |
– |
– |
+ |
– |
– |
SARS-CoV-2 qRT-PCR‡ |
– |
– |
– |
– |
+ |
– |
– |
ELISA, IgG antibodies to Trypanosoma cruzi |
+ |
+ |
+ |
+ |
+ |
+ |
– |
Strout test |
+ |
– |
+ |
+ |
NP |
NP |
– |
qPCR for T. cruzi, parasites/mL§ |
+, 0.5 |
+, 4.55 |
+, 3.25 |
+, 5.4 |
+, 5.8 |
+, 2.63 |
+, 0.5 |
Direct microscopic examination of pericardial fluid¶ | + | + | + | + | NP | NP | NP |
*EKG, electrocardiography; ICU, intensive care unit; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; ND, no data; NP, not performed; qRT-PCR, real-time quantitative reverse transcription PCR; qPCR, quantitative PCR; +, positive; –, negative. †Presence of trypomastigotes. ‡Nasal swab. §Whole blood for T. cruzi DNA detection. ¶Detection of trypomastigotes via pericardiocentesis.
Page created: July 17, 2023
Page updated: August 20, 2023
Page reviewed: August 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.